文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性去势抵抗性前列腺癌(mCRPC)肝转移患者接受177Lu-PSMA-617放射配体治疗的缓解与结局

Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-05-06

回顾性分析28例连续接受177Lu-PSMA-617放射配体治疗的mCRPC肝转移患者,计划方案为4-6周期、间隔6±2周、平均每周期活度6.5±0.5 GBq。肝转移灶完全或部分缓解各6例(21%),疾病稳定1例(4%),肝脏疾病控制率46%。中位肝脏无进展生存期5.7(95%CI 2.2-9.2)个月,中位总生存期11.7(95%CI 3.0-20.4)个月;肝脏疾病控制、2周期后PSA下降≥50%及基线ECOG 0-1与总生存期独立相关。

要点

  • 肝转移灶完全或部分缓解各6例(21%),疾病稳定1例(4%),肝脏疾病控制率46%。
  • 中位肝脏无进展生存期5.7(95%CI 2.2-9.2)个月,中位总生存期11.7(95%CI 3.0-20.4)个月。
  • 肝脏疾病控制、2周期后PSA下降≥50%及基线ECOG 0-1与总生存期独立相关。

核心结论

  • 177Lu-PSMA-617放射配体治疗常可控制肝转移灶,带来较长的肝脏无进展生存期并显著改善总生存期。
  • 肝脏肿瘤负荷(≤25% vs >25%肝体积)与肝脏肿瘤缓解、肝脏无进展生存期或总生存期无明显关系,支持对晚期/终末期mCRPC伴肝转移患者使用177Lu-PSMA-617放射配体治疗。

研究设计与样本

  • 回顾性分析28例连续接受177Lu-PSMA-617放射配体治疗的mCRPC肝转移患者。
  • 计划方案为4-6周期、间隔6±2周,平均每周期活度6.5±0.5 GBq。
  • 肝脏缓解采用实体瘤正电子发射断层扫描改良缓解标准判定,生存分析采用Kaplan-Meier曲线、log-rank检验(p<0.05为显著)及Cox比例风险模型。

主要发现

  • 中位(最小-最大)随访37.5(2.3-50.6)个月。
  • 肝转移灶完全缓解6例(21%)、部分缓解6例(21%)、疾病稳定1例(4%),肝脏疾病控制率46%。
  • 中位肝脏无进展生存期5.7(95%CI 2.2-9.2)个月,中位总生存期11.7(95%CI 3.0-20.4)个月。
  • 肝脏疾病控制组未达到中位总生存期,肝脏疾病进展组中位总生存期为6.4(95%CI 1.6-11.1)个月。
  • 多因素分析中,177Lu-PSMA-617放射配体治疗后的肝脏疾病控制、2周期后PSA下降≥50%及基线体能状态良好(ECOG 0-1)均与总生存期显著独立相关;肝脏肿瘤负荷(≤25% vs >25%肝体积)与肝脏肿瘤缓解、肝脏无进展生存期或总生存期无明显关系。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Little is known about the efficacy of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) against liver metastases of metastatic castration-resistant prostate cancer (mCRPC). We retrospectively analyzed efficacy-related outcomes of 177Lu-PSMA-617 RLT in this setting and potential predictors of those outcomes. METHODS: Twenty-eight consecutive mCRPC patients with liver metastases given 177Lu-PSMA-617 RLT were analyzed retrospectively. Their planned regimen was 4-6 cycles at 6 ± 2-week intervals; the mean activity/cycle was 6.5 ± 0.5 GBq. Hepatic response was determined by modified positron emission tomography response criteria in solid tumors; association of such response with overall survival (OS) was tested, as were relationships of the selected patient, disease, and treatment characteristics with hepatic progression-free survival (PFShep) and OS. Survival analyses used Kaplan-Meier curves, log-rank test at p < 0.05 significance, and Cox proportional-hazards modeling. RESULTS: Median (minimum-maximum) follow-up was 37.5 (2.3-50.6) months. In liver metastases, complete or partial response was observed in 6 patients (21%) each, and stable disease in 1 (4%), for hepatic disease control in 46%. Overall, median (95% confidence interval) PFShep was 5.7 (2.2-9.2) months, and OS, 11.7 (3.0-20.4) months. Patients with hepatic disease control did not reach the median OS, while those with hepatic progressive disease had median OS (95% confidence interval) of 6.4 (1.6-11.1) months. In multivariate analysis, hepatic disease control by 177Lu-PSMA-617 RLT was significantly independently associated with OS, as was a prostate-specific antigen decline of ≥ 50% after 2 RLT cycles, and good baseline performance status (Eastern Cooperative Oncology Group 0-1). Hepatic tumor burden (≤ 25% vs. > 25% of liver volume) had no apparent relationship with hepatic tumor response, PFShep, or OS. CONCLUSION: 177Lu-PSMA-617 RLT frequently controlled liver metastases, resulting in long PFShep and significantly improved OS. Hepatic tumor burden appeared to lack any relationship with treatment efficacy, supporting 177Lu-PSMA-617 RLT of late-stage/end-stage mCRPC with liver metastases.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Khreish F, Kochems N, Rosar F, et al. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 32378019. doi:10.1007/s00259-020-04828-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。